Company intelligence / Profile preview

Stoparkinson Healthcare Systems

San Mateo, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Stoparkinson has developed a non-invasive, wearable neuromodulation device called EARSTIM that alleviates both motor and non-motor symptoms of Parkinson’s disease. The company has completed four significant clinical trials demonstrating clinically meaningful effects and is currently seeking funding for a pivotal FDA study. The product is not yet commercially available.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyWearable neuromodulation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

EarStim

Phase 2

Indications: Parkinson's disease

Beyond the preview

Go deeper on Stoparkinson Healthcare Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stoparkinson Healthcare Systems.

Explore the full profile